Heart:心力衰竭患者流感疫苗接种的疗效分析

2019-08-24 xing.T MedSci原创

由此可见,流感疫苗接种与HF患者全因死亡风险显著降低有关。

尽管治疗进展了数十年,但心力衰竭(HF)是一种具有高发病率、死亡率和经济负担的疾病。流感感染是包括HF在内的心血管(CV)事件的重要触发因素。已经发现流感疫苗接种可降低冠心病患者的CV死亡风险,但HF患者的效果尚不清楚。近日,心脏病领域权威杂志Heart上发表了一篇研究文章,研究人员进行了系统评价以评估流感疫苗接种对HF患者死亡率的影响。

研究人员检索了MEDLINE、Cochrane对照试验登记中心、Cochrane系统评价数据库、健康技术评估和PsycINFO数据库(2018年12月),确定了与未接种疫苗的对照组相比评估HF患者流感疫苗接种疗效的纵向研究。根据ROBINS-I工具评估偏倚风险。研究人员进行了随机效应荟萃分析,以估计汇总HR和95%CI,并使用I2统计数据评估异质性。

荟萃分析纳入了6项队列研究,评估179158例HF患者。流感疫苗接种与全因死亡风险降低相关(HR=0.83; 95%CI为0.76-0.91; I2=75%)。在对CV死亡率(HR=0.92,95%CI为0.73-1.15;2项研究)和全因住院治疗(HR=1.01,95%CI为0.92-1.11;2项研究)的合并分析中流感疫苗的效果并不显著。纳入研究中的大多数结局具有严重的偏倚风险,并且几乎所有评估结局都具有非常低的GRADE评分等级。

由此可见,流感疫苗接种与HF患者全因死亡风险显著降低有关。 

原始出处:

Bárbara Sucena Rodrigues.et al.Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies.Heart.2019.http://dx.doi.org/10.1136/heartjnl-2019-315193

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2019519, encodeId=9fa520195190d, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Oct 14 08:08:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647248, encodeId=ff54164e24823, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Dec 18 05:08:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257875, encodeId=94c5125e875e1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357256, encodeId=4ea8135e256c1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563133, encodeId=3c8c156313301, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032259, encodeId=10551032259c6, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Aug 25 00:08:00 CST 2019, time=2019-08-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2019519, encodeId=9fa520195190d, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Oct 14 08:08:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647248, encodeId=ff54164e24823, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Dec 18 05:08:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257875, encodeId=94c5125e875e1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357256, encodeId=4ea8135e256c1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563133, encodeId=3c8c156313301, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032259, encodeId=10551032259c6, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Aug 25 00:08:00 CST 2019, time=2019-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2019519, encodeId=9fa520195190d, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Oct 14 08:08:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647248, encodeId=ff54164e24823, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Dec 18 05:08:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257875, encodeId=94c5125e875e1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357256, encodeId=4ea8135e256c1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563133, encodeId=3c8c156313301, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032259, encodeId=10551032259c6, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Aug 25 00:08:00 CST 2019, time=2019-08-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2019519, encodeId=9fa520195190d, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Oct 14 08:08:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647248, encodeId=ff54164e24823, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Dec 18 05:08:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257875, encodeId=94c5125e875e1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357256, encodeId=4ea8135e256c1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563133, encodeId=3c8c156313301, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032259, encodeId=10551032259c6, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Aug 25 00:08:00 CST 2019, time=2019-08-25, status=1, ipAttribution=)]
    2019-08-26 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=2019519, encodeId=9fa520195190d, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Oct 14 08:08:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647248, encodeId=ff54164e24823, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Dec 18 05:08:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257875, encodeId=94c5125e875e1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357256, encodeId=4ea8135e256c1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563133, encodeId=3c8c156313301, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032259, encodeId=10551032259c6, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Aug 25 00:08:00 CST 2019, time=2019-08-25, status=1, ipAttribution=)]
    2019-08-26 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=2019519, encodeId=9fa520195190d, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Mon Oct 14 08:08:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647248, encodeId=ff54164e24823, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Dec 18 05:08:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257875, encodeId=94c5125e875e1, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357256, encodeId=4ea8135e256c1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563133, encodeId=3c8c156313301, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Aug 26 12:08:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032259, encodeId=10551032259c6, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Aug 25 00:08:00 CST 2019, time=2019-08-25, status=1, ipAttribution=)]
    2019-08-25 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Lancet:AI系统助力房颤的鉴别

研究发现,AI可提高正常窦性心律期间获得房颤特征的识别率

JACC-Heart Failure:Omega-3脂肪酸可预测心力衰竭风险

临床试验表明,omega-3多不饱和脂肪酸(ω3 PUFAs)可预防冠心病和HF猝死,但仍有争议。在小鼠中,作者证明ω3 PUFA EPA可预防HF模型中的收缩功能障碍和纤维化,但这是否可延伸到人类尚不清楚。

JACC-Heart Failure:营养不良与HFpEF患者心血管风险增加相关

营养不良与各种疾病的不良预后相关,然而,营养不良对射血分数保留的心力衰竭(HFpEF)患者预后的影响尚不清楚。JACC: Heart Failure发表的一项研究旨在探讨营养不良与HFpEF患者不良心血管(CV)事件的关系。

JACC:年轻HFpEF患者更常见于肥胖男性,且猝死率高

虽然,射血分数保留的心力衰竭(HFpEF)被认为是老年人的疾病,但年轻患者也可出现这种综合症。JACC发表的一项研究探讨了HFpEF患者的年龄、临床特征和预后的关系。

NEJM:Serelaxin治疗急性心力衰竭

serelaxin对急性心力衰竭患者心衰恶化及死亡率的影响不显著

Circulation:有或没有心力衰竭或肾功能不全的糖尿病患者的二甲双胍使用情况和临床结局

由此可见,在12156名高CV风险的T2DM患者队列中,使用二甲双胍与全因死亡率降低相关,包括在调整临床变量和生物标志物后,但未降低CV死亡、心肌梗死或缺血性卒中的复合终点发生率。这种关联在既往没有HF或中度至重度CKD的患者中最为明显。